Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Blood (2016) 128 (22): 2224.

https://doi.org/10.1182/blood.V128.22.2224.2224

Published: 2016

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Nicole Engel, MD, Wolfgang Hill, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Anna-Katharina Zoellner, MD, Max Hubmann, MD, Veit Buecklein, MD, Andreas Hausmann, MD, Georg Ledderose, MD, Hans-Jochem Kolb, PhD, Wolfgang Hiddemann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 5839.

https://doi.org/10.1182/blood.V124.21.5839.5839

Published: 2014

Journal Articles

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Max Hubmann, MD, Christina Zeber, Markus Pfirrmann, PhD, Thomas Koehnke, MD, Nicole Engel, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Stephanie Schneider, PhD, Annika Dufour, PhD, Evelyn Zellmeier, Roland Reibke, MD, Hans-Jochem Kolb, PhD, Marion Subklewe, MD, Michael Fiegl, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Johanna Tischer, MD

Blood (2014) 124 (21): 1178.

https://doi.org/10.1182/blood.V124.21.1178.1178

Published: 2014

Journal Articles

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Anna-Katharina Zoellner, Susanne Fritsch, MD, Dusan Prevalsek, MD, Nicole Engel, MD, Roland Reibke, MD, Christina T Rieger, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, Martin Dreyling, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2013) 122 (21): 4544.

https://doi.org/10.1182/blood.V122.21.4544.4544

Published: 2013

Journal Articles

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Johanna Tischer, MD, Susanne Fritsch, MD, Dusan Prevalsek, MD, Max Hubmann, MD, Veit Bücklein, Anna K Zöllner, MD, Christoph Schulz, MD, Roland Reibke, MD, Nicole Engel, MD, Christina T Rieger, MD, PhD, Christoph Schmid, MD, PhD, Georg Ledderose, MD, Wolfgang Hiddemann, MD, PhD, Andreas Hausmann, MD

Blood (2012) 120 (21): 3071.

https://doi.org/10.1182/blood.V120.21.3071.3071

Published: 2012

Journal Articles

Characterization of CD6-Negative Suppressor Cells Facilitating HLA-Haploidentical Stem Cell Transplantation.

Iris Bigalke, MD, Christine Falk, PhD, Dominik ter Meer, PhD, Marina Leeping, Dusan Prevalsek, MD, Johanna Tischer, MD, Hans-Jochem Kolb, MD, PhD

Blood (2005) 106 (11): 2909.

https://doi.org/10.1182/blood.V106.11.2909.2909

Published: 2005

NARROW

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Characterization of CD6-Negative Suppressor Cells Facilitating HLA-Haploidentical Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Allogeneic Transplantation in Elderly Patients with AML and MDS Comparing Reduced-Intensity Conditioning with Flamsa-Busulfan Versus Fludarabine/BCNU/Melphalan

Quantitative Monitoring By RT-PCR of Molecular Markers on Day +100 after Allogeneic Stem Cell Transplantation Predicts Outcome in Patients with Acute Myeloid Leukemia

Sequential Therapy Combining Clofarabine and HLA-Haploidentical Hematopoietic Stem Cell Transplantation In The Treatment Of Refractory and Advanced Lymphoma: Feasibility, Toxicity and Early Outcome

Clofarabine Cytoreduction Followed by a Second Transplant Using Haploidentical Donors for Relapsed Acute Leukemia After First Allogeneic Hematopoietic Stem Cell Transplantation: Early Outcome, Infection and Toxicity.

Characterization of CD6-Negative Suppressor Cells Facilitating HLA-Haploidentical Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only